Clinical trials are complex. They are costly. They take too long. They favor white people. Wait. What? According to an article in the New York Times, many cancer clinical trials are heavily weighted towards the white population. Why? They cite several reasons: most top cancer centers are not in rural locations; trials sponsored by industry do not have to have a specific mix of races; many minorities have chronic diseases that may exclude them from cancer trials. But the fact remains that cancer trials are weighted toward Caucasians. Maybe they’re easier to enroll, but should that matter? Maybe. Check out the FastPoll™ below and tell us what you think.